Greenhill has considerable transaction experience and a global network of corporate relationships in the Healthcare sector.  Our managing directors and professionals in North America, the United Kingdom and Continental Europe have executed many of the most significant and complex transactions for some of the leading companies in the industry.

Below we highlight a few of the transactions on which we have advised in this area:

DATE	$		COMPANY/ASSET ACQUIRED		ACQUIROR
12-Jul-2010 Closed	NA		Breast Care Business of Ethicon-Endo Surgery Advised GTCR and Devicor Medical Products, Inc., a portfolio company of GTCR, on the acquisition of the Breast Care Business of Ethicon-Endo Surgery		Devicor Medical Products, Inc. (a GTCR portfolio company)
05-Apr-2010 Closed	$225 million		Medegen, Inc Advising Medegen, Inc., a medical device company that develops, manufactures and markets clinically superior disposable intravenous therapy products on its sale to CareFusion, a global medical devices company		CareFusion Corporation
23-Feb-2010	NA		Heartscape Technologies, Inc. Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company		Roper Industries, Inc.
04-Jan-2010 Pending	$11.2 billion+		Alcon Inc. Advising the Independent Directors of Alcon Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis, a global pharmaceutical company		Novartis AG
09-Nov-2009	$327 million		Enzon Pharmaceuticals, Inc. Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company		Sigma-Tau Pharmaceuticals
23-Jun-2009	$155 million		Monogram Biosciences, Inc. Advised LabCorp on the acquisition of Monogram Biosciences, a molecular diagnostics company focused on guiding and improving the treatment of serious infectious diseases and cancer		Laboratory Corporation of America Holdings
12-Mar-2009	$46.9 billion		Genentech, Inc. Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company		Roche Holding Ltd.
01-Oct-2008	$53 million		Biotage (Biosystems division) Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research		Qiagen NV
12-Jun-2008	$6.7 billion		Applied Biosystems Group Provided fairness opinion to the Board of Directors of the Applera Corporation on the merger of its Applied Biosystems business, which serves the life science industry, with the Invitrogen Corporation, creating a global leader in biotechnology reagents and systems		Invitrogen Corporation
22-Jan-2008	$3.4 billion		Ventana Medical Systems, Inc. Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a U.S. based provider of histopathology diagnostic equipment		Roche Holding Ltd.
21-May-2007 Pending	$454 million		Taro Pharmaceutical Industries Advising Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company		Sun Pharmaceutical Industries Ltd.
25-Jan-2007	$3.3 billion		Cardinal Health, Inc., Pharmaceutical Technologies and Services division Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries		The Blackstone Group
06-Nov-2006	$4.2 billion		Kos Pharmaceuticals, Inc. Advised Kos Pharmaceuticals, Inc., a specialty pharmaceutical provider of cardiovascular and respiratory drugs, on its sale to Abbott Laboratories		Abbott Laboratories
24-Mar-2006	$21.2 billion		Schering AG Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany		Bayer AG